Dr Michael Gibson
We interview Dr Michael Gibson (Harvard Medical School, Massachusetts, USA) to discuss our roundup of major clinical trials from the American Heart Association meeting – one of the highlights in the cardiology year. The podcast covers the ever-popular late breaking sessions, which are always the subject of great interest.
Professor John Camm
New advances in the treatment of atrial fibrillation, including new guidelines, a ‘machine learning’ risk scheme and whether we are anticoagulating the right patients, are discussed by Professor John Camm (St George’s University of London).
Dr Jubin Joseph
The potential of imaging to help avoid unnecessary coronary angiography is discussed by Dr Jubin Joseph (St Thomas’ Hospital, London) as well as the continuing debate about the benefits of bare metal versus drug-eluting stents, which was thrown into the spotlight again at the ESC.
Dr Jubin Joseph
Results of two clinical studies to evaluate the possible benefits of telemonitoring in the management of heart failure are discussed by Dr Jubin Joseph (St Thomas’ Hospital, London).
Professor Patrick M Moriarty
A reduction in the costly dialysis-like treatment of lipoprotein apheresis looks possible for FH patients following results from a study with the PCSK9 inhibitor alirocumab. Professor Patrick M Moriarty (University of Kansas Medical Center, USA) discusses the implications.
Dr Terry McCormack, Professor Barbara Casadei
New advances in hypertension, including a breakthrough for the treatment of resistant hypertension is discussed by Dr Terry McCormack, while Professor Barbara Casadei discusses the different presentation and co-morbidities of cardiovascular disease in women.